Haemonetics (NYSE: HAE) reported Q1 EPS of $0.59, $0.17 better than the analyst estimate of $0.42. Revenue for the quarter came in at $229.3 million versus the consensus estimate of $219.95 million.

GUIDANCE:

Haemonetics sees FY2019 EPS of $2.00-$2.30, versus the consensus of $2.17.

For earnings history and earnings-related data on Haemonetics (HAE) click here.